

INSIGHTS IN ESSENTIAL MEDICINE AVAILABILITY AND ACCESSIBILITY FROM ESMO ANTINEOPLASTIC MEDICINES STUDY 2.0

Nathan Cherny, on behalf of the collaborating partners

Shaare Zedek Medical Center, Jerusalem, Israel



DECLARATION OF INTERESTS

Nathan Cherny

No conflicts to disclose







PROJECT RATIONALE



ESMO is committed to assuring timely and optimal treatment to cancer patients The availability of antineoplastics directly affects the daily practice of clinicians and their ability to treat cancer patients



Affordability of medications impacts the equitable distribution of cancer care





For more information : https://www.esmo.org/policy/accessibility-and-availability-of-medicines

COMMON ISSUES WITH ANTI-NEOPLASTIC AGENTS

LIMITATIONS IN FORMULARY

No comprehensive mapping of formularies

ACTUAL AVAILABILITY AND AFFORDIBILITY



BARRIERS OF ACCESSIBILITY


shortages distribution manufacturing

AIMS OF THE STUDY

To **update** data regarding availability of cancer medicines in Europe, and the "Rest of the World" Factors adversely Formulary Availability of Patient 'out-ofimpacting cancer availability of pocket' cost for medication for medicine licensed antithe medication patients with a availability neoplastic medicines valid prescription

STUDY DEVELOPMENT

Modelled on previous ESMO Consortium Study on the Availability of Anti-Neoplastic Medicines (ANMS)








Ref: Cherny, Ann Onc 2016 (Europe); Cherny, Ann Onc 2017 (Global); Chern, Ann Onc 2013 (Global Opioid Policy Initiative)

DISEASE AREAS SURVEYED





EXAMPLE OF SURVEY: METASTIC BREAST CANCER

	Is this medicine available for this indication?	(wha	st of the n t proporti es the av	on of the	full retail	price	most	patients in	your co	dicine when neo untry (can the pa when it is pres	atient	If the medicine is not always available, what is the main reason for this?						Has the availability of this medicine been impacted by COVID-19?		
	Yes No	Free	<25% cost	25- 50% cost	>50% cost but less than full cost	Full cost	Always	Usually	Half the time	Occasionally	Never	No / unreliable supplier * (1)	No commerical motive *(2)	Parallel export *(3)	Manufacturing issues *(4)	Budget capitation *(5)	Do not know	Yes	No	
Albumin- bound paclitaxel	ОС	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abemaciclib	ОC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Alpelisib	ОC	0	0	0	0	0	0	0	0	0	0	0	0	\bigcirc	0	0	0	0	0	
Anastrozole		$ \circ $	0	0	0	0	0	0	0	0	0		\circ	0	0	0	0	0	0	
Atezolizumab	0 C	$ \circ $	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Bevacizumab Bevacizumab (and its quality- assured biosimilars)	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Eribulin	O C	0	\bigcirc	0	0	0	0	0	0	\bigcirc	\bigcirc	0	\bigcirc	0	0	0	0	0	0	
Everolimus	O C	0	0	0	0	0	0	\bigcirc	0	\bigcirc	\bigcirc	0	\circ	\bigcirc	\bigcirc	0	0	0	\bigcirc	
Examestane	0 0	0	0	0	0	Ο	0	0	0	\circ	0	0	\bigcirc	0	\circ	0	Ο	0	0	
Fulvestrant	0 C	0	0	0	0	0	0	0	0	0	0	0	\bigcirc	0	0	0	0	0	0	



IDENTIFICATION OF DATA REPORTERS



PEER REVIEW

The peer review process is essential to support the robustness of the information provided, to indicate discrepancies in the data, and to provide additional information on the actual situation in the various countries.



The preliminary data were posted on the ESMO website for external validation in August 2023, for a month



Invitations were sent to all members of the collaborating partner organisations, to those who were invited to complete the survey (both those who completed and those who didn't) and was open to all ESMO members to review the data and submit any correction or amendment




Amendments were collated, crosschecked, and incorporated into the final results



PEER REVIEW - RESULTS

269 experts from 107 countries completed the peer review – **17 new countries**





DATA COLLECTION AND MANAGEMENT

Electronic dissemination of survey and automated data entry

Crosschecking data entry and identification of discrepancies between reporters


Representative data presented

Preliminary report at #ESMO 2022

Collection of missing reports and open peer review of collated data

Final data report #ESMO 2023

COLOUR-CODED, TABULATED DATA PRESENTATION



Methodology similar to that developed by ESMO for studies on the availability of opioids for cancer pain management and antineoplastic agents Tables with colour-coded, tabulated data

Readily allows crosscounty comparisons

Data presentation facilitates tracking changes in availability over time



"WHO MODEL LIST OF ESSENTIAL MEDICINES"

Often referred to as the Essential Medicines List (EML)



Compilation of medications that WHO deems necessary for a basic healthcare system to function effectively



- These medicines are considered essential because
 - 1. they address the most important healthcare needs
 - 2. considered cost-effective, safe, and readily available



EML is updated regularly to reflect current medical knowledge and changing health priorities



WHO EML HISTORY




- for primary healthcare
- List did not comprehensively cover cancer treatment options

1977-2023

- Over the years **more cancer** medicines
- Initially chemotherapy agents ٠
- Growing recognition of the ٠ importance of targeted therapies



ANTI-CANCER MEDICINES IN THE WHO EML



EML=Model List of Essential Medicines. EMLc=Model List of Essential Medicines for Children. UICC=Union for International Cancer Control.



Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, et al. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022;10(12):e1860-e6.

ANTI-CANCER MEDICINES FOR ADULT SOLID TUMORS ON THE WHO EML

kics (X
gemcitabine
fosfamide
rinotecan
eucovorin
nethotrexate
oxaliplatin
oaclitaxel
vinblastine
vincristine
vinorelbine
vinorelbine



abiraterone

anastrozole

bicalutamide

enzalutamide

flutamide

goserelin

tamoxifen

BIOLOGICAL nivolumab pembrolizumab afatinib erlotinib everolimus gefitinib imatinib trastuzumab



USES OF THE WHO EML



National formularies

- Many nations incorporate the WHO EML into their national drug policies and procurement processes
- Helps governments to prioritise for medicines availability and affordability within their healthcare systems



NGOs and donors

Can identify priorities in efforts to provide healthcare assistance and support to countries in need

The EML is a valuable tool for promoting access to essential medicines and improving healthcare outcomes globally



RESULTS 2023



AVAILABILITY AND ACCESSIBILITY OF CANCER MEDICINES

2023 update




252 experts from 110 countries



Peer review with 269 experts from 106 countries

Total of countries surveyed 127



COST AND AVAILABILITY OF MULTI-USE ESSENTIAL MEDICINES

High-income

Country	CarboPl	CisPl	OxaliPl	Dox	5FU	Capecit	Gemcit	Irino	PacliTx	DoceTx
Australia	Free	Free	Free	Free	Free	<25% cost	Free	Free	Free	Free
Austria	Free									
Belgium	Free									
Canada	Free									
Chile	<25% cost									
Taiwan	Free									
Croatia	Free									
Cyprus	Free									
Czech Republic	Free									
Denmark	Free									
Estonia	Free									
Finland	Free	Free	Free	Free	Free	<25% cost	Free	Free	Free	Free
France	Free									
Germany	Free									
Greece	Free									
Hungary	Free									
Iceland	Free									
Ireland	Free									
Israel	Free									
Italy	Free									
Japan	<25% cost									
Korea	<25% cost									
Kuwait	Free									
Latvia	Free									
Lithuania	Free									
Luxembourg	Free									
Malta	Free									
Netherlands	Free									
New Zealand	Free	Free	Free	Free	Free	<25% cost	Free	Free	Free	Free
Norway	Free									
Oman	Free									
Poland	Free									
Portugal	Free									
Qatar	Free									
Saudi Arabia	Free									
Singapore	Free									
Slovakia	Free									
Slovenia	Free									
Spain	Free									
Sweden	Free									
Switzerland	Free									
UAE	Free									
United Kingdom	Free									
USA	<25% cost									

Upper-middle income

Country	CarboPl	CisPl	OxaliPl	Dox	5FU	Capecit	Gemcit	Irino	PacliTx	DoceTx
Albania	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Argentina	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Armenia	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	Free	Free	>50% but less than full cost	>50% but less than full cost	>50% but less than full	>50% but less than full cost	>50% but less than full cost
Azerbaijan	Free	Free	Free	Free	Free		Free	Free	Free	Free
Belarus	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Bosnia + HGV	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Botswana	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Brazil	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Bulgaria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
China	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Colombia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Costa Rica	<25% cost	<25% cost	<25% cost	Free	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Cuba	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Ecuador										
Georgia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Guatemala	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Iraq	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Jamaica	Free	Free	Free	Free	Free	Free	Free		Free	>50% but less than full cost
Kazakhstan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Libya	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Malaysia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Mexico	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Moldova	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Montenegro	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Namibia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
North Macedonia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Peru	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Romania	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Russia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Serbia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
South Africa	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Suriname	<25% cost	Free	25-50% cost	Free	Free	Free	25-50% cost		25-50% cost	25-50% cost
Thailand	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Türkiye	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Turkmenistan	Full cost	Free		Free	Free	Free	>50% but less than full cost		Full cost	25-50% cost

Free	
<25% cost	
25-50% cost	
>50% but less than full cost	
Full cost	
Not available	

Low- and Lower-middle income

Country	CarboPI	CisPl	OxaliPI	Dox	5FU	Capecit	Gemcit	Irino	PacliTx	DoceTx
Algeria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Bangladesh	Full cost	Full cost		Full cost		Full cost			Full cost	Full cost
Bolivia	>50% but less then full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less then full cost	>50% but less than full cost	>50% but les than full cos
Cambodia	Full cost									
Cameroon	Full cost									Full cost
Egypt	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
El Salvador	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Ghana	Full cost				25-50% cost	<25% cost			25-50% cost	25-50% cost
Haiti	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Honduras	Full cost			Full cost	Full cost				Full cost	Full cost
India	Full cost			Full cost	Full cost				Full cost	
Indonesia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Iran	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Kenya	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost
Lebanon	>50% but less then full cost	Full cost	>50% but less three full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	>50% but les
Mongolia	Free Free	Free	Free Free	Free	Free	Free	Free	Free	Free	Free Free
Morocco	25-50% cost	25-50% cost	<25% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	<25% cost	25-50% cost
Mvanmar	25-50% cost	Free	>50% but less	<25% cost	Free	Full cost	>50% but less	>50% but less	>50% but less	Full cost
Nepal	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Nicaragua	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Nigeria	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Pakistan	<25% cost	<25% cost	25-50% cost	25-50% cost	<25% cost	<25% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost
Palestine	Free	Free	Free	Free	Free	Free	Free	Free	Free	Eree
Papua New Guinea	>50% but less	>50% but less	Full cost	>50% but less	>50% but less	Full cost	Full cost	Full cost	Full cost	Full cost
Philippines	than full cost	than full cost	Full cost	than full cost	than full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Sri Lanka	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Tunisia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Tanzania	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Uzbekistan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Vanuatu	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost		<25% cost	<25% cost
Vietnam	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Zambia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Zimbabwe	Free Full cost	Full cost	Free Full cost	Full cost	Full cost	Full cost	Free Full cost	Full cost	Full cost	Full cost
Afghanistan	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Argnanistan Burkina Faso	Full cost	Full cost	Full cost	Full cost	Full cost	TUT COS	Full cost	Full cost	Full cost	Full cost
Ethiopia	>50% but less	>50% but less	>50% but less	>50% but less	>50% but less	>50% but less	>50% but less	>50% but less	350% but less	>50% but les
Liberia	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost <25% cost	than full cost
	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Madagascar Malawi	Full cost	Full cost	Full cost	Full cost Free	Full cost Free	Full cost Free	Full cost	Full cost Free	Full cost Free	Full cost
Malawi Niger	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost	Free Full cost
Niger Rwanda	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	
	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but less	Full cost >50% but les
Somalia	than full cost	than full cost	than full cost	than full cost	than full cost	than full cost	than full cost	than full cost	than full cost	than full cos
Sudan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Syria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Uganda	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Yemen	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Venezuela	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free

ACCESSIBILITY OF MULTI-USE ESSENTIAL MEDICINES

High-income

ountry CarboPI CisPI OxaliPI Dox 5FU Capeci Gemcit Irino PacliTx DoceT Australia Always Austria Always Always Always Aways Always Always Belgium Always Always Always Always Always Always Always Canada Always Always Always Chile Always Always Always Always Always Always Always Taiwan Always Always Alway Always Always Always Always Always Croatia Aways Always Always Always Always Always Aways Always Alway: Cyprus Always Always Always Always. Always Always Always Always Czech Republic Always Always Always Always Always Always Denmark Usually Usually Always Usually Usually Estonia Aways Always Always Always Always Always Always Always Always Always Finland kuali I kually (Kually Usually France Always Alway: Always Always Always Always Always Always Always Germany Always Always Always Always Always Always Always Always Greece Aways Alway: Always Always Always Always Always Always Always Hungary Always Always Always Always Always Always Always Always Iceland Always Always Always Always Always Always Always Always Alway: Always Ireland Always Alway Always Alware Always Always Always Always Israel Aways Always Aluctor Always Always Aways Always Always Always Italy Always Always Always Alware Always Always Alwaye Always Always Japan Always Always Alway: Always Always Always Always Korea Always Always Always Always Always Always Always Always Kuwait Always Always Always Always Always Always Always Always Always Latvia Usually Usually Usuali Usually Usually Usualli Always Always l ithuania Always Luxembourg Always Always Always Always Always Always Always Always Malta Always Always Alway: Always Always Alwaya Always Always Netherlands Always Always Always Always Always Always Always Always New Zealand Always Always Always Always Always Always Always Always Norway Always Always Always Always Always Oman Always Always Usuali Always Always Usually Usually Poland Always Always Always Always Always Always Always Always Alway: Portuga Always Alway: Always Always Always Aways Always Always Always Qatar Always Δίωσυ Always Always Always Always Always Always Always Saudi Arabia Always Always Always Always Always Always Singapore Always Always Always Always Always Always Always Slovakia Always Always Always Always Always Always Always Always Slovenia Always Always Always Always Always Always Alway: Always Spain Always Always Always Always Always Always Always Sweden Always Always Always Always Always Alway Always Always Always Switzerland Always Always Always Always Always Always Always Always UAE Always Always Always Always Aways Always Always Always United Kingdom Always Always Always. Always Always Always Always Abacava Always USA Always Always Awars Always

Upper-middle income

Low + Lower-middle income


Country	CarboPI	CisPl	OxaliPl	Dox	5FU	Capecit	Gemcit	Irino	PacliTx	DoceTy
Albania	Always	Always	Always	Always	Always	Always	Always	Usually	Always	Always
Argentina	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Armenia	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Azerbaijan	Always	Always	Always	Always	Always	Usually	Always	Always	Always	Always
Belarus	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Bosnia + HGV	Always	Always	Always	Always	Usually	Usually	Always	Always	Always	Always
Botswana	Usually	Always	Usually	Always	Always	Usually	Usually	Usually	Always	Usually
Brazil	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Bulgaria	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
China	Always	Always	Always	Usually	Always	Always	Always	Always	Always	Always
Colombia	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
Costa Rica	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Cuba	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
Ecuador										
Georgia	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Guatemala	Usually	Usually	Always	Always	Always	Always	Usually	Usually	Always	Always
Iraq	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
Jamaica	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Half the time	Usually	Usually
Kazakhstan	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Libya	Usually	Usually	Half the time	Half the	Half the	Usually	Half the time	Half the time	Half the time	Half the tir
Malaysia	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Mexico	Usually	Half the time	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
Moldova	Always	Always	Usually	Usually	Always	Always	Usually	Half the time	Usually	Usually
Montenegro	Usually	Always	Usually	Always	Usually	Always	Always	Usually	Usually	Usually
Namibia	Always	Always	Usually	Always	Always	Always	Always	Always	Always	Always
North Macedonia	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Peru	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Romania	Usually	Usually	Always	Usually	Usually	Usually	Usually	Always	Always	Usually
Russia	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Serbia	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
South Africa	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually	Usually
Suriname	Usually	Usually	Usually	Usually	Always	Usually	Half the time		Usually	Half the tir
Thailand	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Türkiye	Always	Always	Always	Always	Always	Always	Always	Always	Always	Always
Turkmenistan	Occasionally	Half the time		Usually	Usually	Half the time	Occasionally		Half the time	Occasiona

Always	
Usually	
Half the time	
Occasionally	
Never	
Not available	

Country	CarboPI	CisPl	OxaliPl	Dox	5FU	Capecit	Gemcit	Irino	PacliTx	DoceTx
Algeria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Bangladesh	Full cost									Full cost
Bolivia	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than	>50% but less than full cost					
Cambodia	Full cost		Full cost						Full cost	Full cost
Cameroon	Full cost		Full cost			Full cost			Full cost	Full cost
Egypt	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
El Salvador	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Ghana	Full cost				25-50% cost	<25% cost		Full cost	25-50% cost	25-50% cost
Haiti	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Honduras	Full cost									Full cost
India	Full cost		Full cost			Full cost		Full cost	Full cost	Full cost
Indonesia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Iran	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Kenya	25-50% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost					
Lebanon	>50% but less than full cost		>50% but less than full cost						Full cost	>50% but less than full cost
Mongolia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Morocco	25-50% cost	25-50% cost	<25% cost	25-50%	25-50% cost	25-50% cost	25-50% cost	25-50% cost	<25% cost	25-50% cost
Myanmar	25-50% cost	Free	>50% but less than full cort	<25% cost	Free	Full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than full cort	Full cost
Nepal	Full cost								Full cost	Full cost
Nicaragua	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Nigeria	Full cost		Full cost			Full cost		Full cost	Full cost	Full cost
Pakistan	<25% cost	<25% cost	25-50% cost	25-50%	<25% cost	<25% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost
Palestine	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Papua New Guinea	>50% but less than full cost	>50% but less than full cort	Full cost	>50% but	>50% but less than full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Philippines	Full cost		Full cost			Full cost		Full cost	Full cost	Full cost
Sri Lanka	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Tunisia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Tanzania	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Uzbekistan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Vanuatu	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost		<25% cost	<25% cost
Vietnam	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Zambia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Zimbabwe	Full cost		Full cost			Full cost				Full cost
Afghanistan	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Burkina Faso	Full cost	Full cost	Full cost	Full cost				Full cost	Full cost	Full cost
Ethiopia	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than	>50% but less than full cost					
Liberia	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Madagascar	Full cost									Full cost
Malawi	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Niger	Full cost									Full cost
Rwanda	Full cost		Full cost					Full cost	Full cost	Full cost
Somalia	>50% but less than full cost	>50% but less than full cost	>50% but less than full cost	>50% but less than	>50% but less than full cost					
Sudan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Syria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Uganda	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Yemen	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Venezuela	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free

ESSENTIAL MEDICINES BIOLOGICAL THERAPIES

With high ESMO-MCBS scores (4-5 non-curative setting and A –B curative setting)





COST and AVAILABILITY

fatani

Free

25% cost

:25% cost

Free

Free Free

Free

Free

Free

Free

:25% cost

High-income

	BREAST		MELA	NOMA			LUNG	
Country	Trastuzumab +BS		Nivo	Pembro		Erlotinib	Gefitinib	A
Australia	Free		Free	Free	1	<25% cost	<25% cost	<
Austria	Free		Free	Free		Free	Free	
Belgium	Free		Free	Free		Free	Free	
Canada	Free		Free	Free		Free	Free	
Chile	Free		Free	Free		Free	Free	
Taiwan	Free		Free	Free		Free	Free	
Croatia	Free		Free	Free		Free	Free	
Cyprus	Free		Free	Free		Free	Free	
Czech Republic	Free		Free	Free		Free	Free	
Denmark	Free		Free	Free		Free	Free	
Estonia	Free					Free	Free	
Finland	Free		Free	Free		<25% cost	<25% cost	
France	Free		Free	Free		Free	Free	
Germany	Free	1	Free	Free	1	Free	Free	
Greece	Free		Free	Free		Free	Free	
Hungary	Free		Free	Free		Free	Free	
Iceland	Free		Free	Free		Free	Free	
Ireland	Free	1	Free	Free	1	Free	Free	
Israel	Free	1	Free	Free	1	Free	Free	
Italy	Free	1	Free	Free	1	Free	Free	
Japan	<25% cost	1	<25% cost	<25% cost	1	<25% cost	<25% cost	<
Korea	<25% cost		<25% cost	<25% cost	1	<25% cost	<25% cost	~
Kuwait	Free	1	Free	Free	1	Free	Free	
Latvia	Free	1	Free	Free	1	Free	Free	
Lithuania	Free	1	Free	Free	1	Free	Free	
Luxembourg	Free		Free	Free		Free	Free	
Malta	Free		Free	Full cost		Free		
Netherlands	Free	1	Free	Free	1	Free	Free	
New Zealand	Free	1	Free	Free	1	<25% cost	<25% cost	
Norway	Free	1	Free	Free	1	Free	Free	
Oman	Free		Free	Free		Free	Free	
Poland	Free		Free	Free	l	Free	Free	
Portugal	Free	1	Free	Free	1	Free	Free	
Qatar	Free		Free	Free		Free	Free	
Saudi Arabia	Free		Free	Free		Free	Free	
Singapore	Free		>50% cost but	>50% cost but		Free	Free	25
Slovakia	Free	1	Full cost	Free	1	Free	Free	
Slovenia	Free	1	Free	Free	1	Free	Free	
Spain	Free	1	Free	Free	1	Free	Free	
Sweden	Free	1	Free	Free	1	Free	Free	
Switzerland	Free	1	Free	Free	1	Free	Free	
UAE	Free		Free	Free		Free	Free	
United Kingdom	Free		Free	Free		Free	Free	
USA	<25% cost		<25% cost	<25% cost		<25% cost	<25% cost	
		1			1		and the second	

Upper-middle income

	BREAST	MELA	NOMA		LUNG	
Country	Trastuzumab +BS	Nivo	Pembro	Erlotinib	Gefitinib	Afatanib
Albania	Free	Full cost	Free	Free		Full cost
Argentina	Free	Free	Free	Free	Free	Free
Armenia	Full cost	Full cost	Full cost	Full cost		
Azerbaijan	Full cost	Full cost	Full cost	Full cost		
Belarus	Free	Free		Free		
Bosnia + HGV	Free	Free	Free	Free		
Botswana	Free		Free			
Brazil	Free	Free	Free	Free	Free	Free
Bulgaria	Free	Free	Free	Free	Free	Free
China	<25% cost	Full cost	<25% cost	<25% cost	<25% cost	<25% cost
Colombia	Free	Free	Free	Free	Free	Free
Costa Rica	Free		<25% cost	Free	25-50% Cost	25-50% Cost
Cuba	Free					
Ecuador	Free		Free			Free
Georgia	<25% cost	Full cost	Full cost	Free		Full cost
Guatemala	Full cost					
Iraq	Free	Free	Free	Free	Free	
Jamaica	Free	Full cost	Full cost	Full cost		
Kazakhstan	Free	Full cost	Free	Free	Free	Free
Libya	Full cost	Full cost	Full cost	Full cost		
Malaysia	<25% cost	Full cost	Full cost	Full cost		<25% cost
Mexico	Free	Free	Free	Free	Free	Free
Moldova						
Montenegro	Free		Free	Free	Free	
Namibia	<25% cost					
North Macedonia	Free	Full cost	Free	Free	Free	Full cost
Peru	Free	Full cost	Full cost	Free	Full cost	
Romania	Free	Free	Free	Free	Free	Free
Russia	Free	Free	Free	Free	Free	Free
Serbia	Free	Free	Free	Free	Free	Free
South Africa	<25% cost	Full cost	Full cost	Full cost	Full cost	Full cost
Suriname	Full cost					
Thailand	<25% cost	Full cost	Full cost	Free	Free	Full cost
Türkiye	Free	Free		Free	Free	Free
Turkmenistan	Free	Full cost	Full cost	Full cost	Full cost	Full cost

Free	
<25% cost	
25-50% cost	
>50% but less than full cost	
Full cost	
Not available	

Low + Lower-middle income

Algeria Banglades

Bolivia Cambodia

Egypt

Haiti

India Indonesia

Iran Kenya Lebanon

Cameroon

El Salvado Ghana

Honduras

Mongolia

Morocco

Myanmar Nepal

Nicaragua

Nigeria Pakistan

Palestine

Papua Nev

Philippines

Sri Lanka

Tanzania Uzbekistar

Vanuatu Vietnam

Zambia

Zimbabwe

Afghanista Burkina Fa

Ethiopia

Liberia Madagasca Malawi

Niger Rwanda

Somalia

Uganda

Yemen

Venezuela

Sudan Syria

Tunisia

	BREAST	MELA	NOMA		LUNG	
	Trastuzumab		Pembro	Erlotinib	O distantin	Afa
	+BS	Nivo	Pembro	Eriotinib	Gefitinib	AIG
	Free			Free	Free	
h	Full cost	Full cost		Full cost		
	Full cost			Full cost		
	Full cost	Full cost	Full cost	Full cost	Full cost	F
	Full cost	Full cost	Full cost			
	Free	Full cost	Full cost	25-50% cost	25-50% cost	F
r	Free			Free	Free	
	Free			Full cost		
	Full cost					
	Full cost		Full cost			
	Full cost	Full cost	Full cost	Full cost	Full cost	F
	Free	Full cost	Full cost	Free	Free	
	<25% cost	Full cost >50% cost but	Full cost >50% cost but	<25% cost	Full cost	
	25-50% cost	less than full	less than full	25-50% cost	25-50% cost	25-
	<25% cost Free					
	Free		-250/	-25%	Full cost <25% cost	
			<25% cost	<25% cost	<25% COSt	
	Full cost	Full cost	Full cost	Full cost	Full cost	F
	Free	Full cost	Full cost	Full cost	Full cost	
	Full cost	T GH COAC		Full cost	Tuncost	
	>50% cost but less than			>50% but less	>50% but less	
	full cost	Full cost	Full cost	than full cost	than full cost	F
	Free	Free	Free	Free	Free	
v Guinea	Full cost >50% cost but less than		>50% cost but	Full cost	Full cost	
s	full cost		less than full	Full cost	Full cost	F
	Free					
				Free		
	Free	Full cost	Full cost		Full cost	
ו (Free	Full cost	Full cost			
	25-50% cost 25-50% cost	Full cost	Full cost	25-50% cost	25-50% cost	25-
	25-50% COSt	Full COSt	Full COSt	20-50% COSt	20-00% C0St	25-
•	Full cost	Full cost	Full cost	Full cost		
ın	Full cost	Full Cost	PullCost	Puil Cost		
iso	Full cost	Full cost	Full cost	Full cost	Full cost	E
ar	Full cost	Full cost	Full cost	Full cost	Full cost	F
	Free					
	Full cost	Full cost	Full cost	Full cost		
	Free					
				Free		
	Free	25-50% cost	Full cost	Free	Free	F
	Full cost	Full cost	Full cost	Full cost	Full cost	F

ACCESSIBILITY

High-income

fatanil

Always

Always

Always

Always

Always

Always

Al ways Al ways

Always

Usually

Always

Always

Always

casionall

f the tim

Always

casionall

casionall

Always

Always

Always

Always

Always

Always

Always

Always

Usually

	BREAST		MELA	NOMA			LUNG	
Country	Trastuzumab +BS		Nivo	Pembro		Erlotinib	Gefitinib	A
Australia	Always		Always	Always		Always	Always	
Austria	Always		Always	Always	1	Always	Always	
Belgium	Always	1	Always	Always	1	Always	Always	
Canada	Always		Always	Always		Always	Always	
Chile	Always		Usually	Usually	1	Always	Always	
Taiwan	Always		Always	Always		Always	Always	
Croatia	Always		Always	Always	1	Always	Always	
Cyprus	Always		Half the time	Always	1	Always	Always	на
Czech Republic	Always		Always	Always	1	Always	Always	
Denmark	Usually		Always	Always	1	Always	Always	
Estonia	Always		Always	Always	1	Always	Always	
Finland	Always	1	Always	Always	1	Usually	Usually	
France	Always	1	Always	Always	1	Always	Always	
Germany	Always		Always	Always	1	Always	Always	
Greece	Always		Always	Always	1	Always	Always	
Hungary	Always		Always	Always	1	Always	Always	00
Iceland	Always		Always	Always	1	Always	Usually	
Ireland	Always		Always	Always	1	Always	Usually	на
Israel	Always		Always	Always	1	Always	Always	
Italy	Always		Always	Always	1	Always	Always	
Japan	Always		Always	Always	1	Always	Always	
Korea	Always		Always	Always	1	Always	Always	
Kuwait	Always		Always	Always	1	Always	Always	
Latvia	Always		Usually	Usually		Usually	Usually	
Lithuania	Always		Always	Always		Always	Always	
Luxembourg	Always		Always	Always	1	Always	Always	
Malta	Always		Always	Usually	1	Always		
Netherlands	Always		Always	Always	1	Always	Always	
New Zealand	Always		Always	Always		Always	Always	
Norway	Always		Always	Always	1	Always	Always	
Oman	Always		Always	Always	1	Always	Always	
Poland	Always		Always	Always	1	Always	Always	
Portugal	Always		Always	Always	1	Always	Always	
Qatar	Always		Always	Always	1	Always	Occasionally	00
Saudi Arabia	Always		Always	Always	1	Always	Usually	00
Singapore	Always		Always	Always		Always	Always	
Slovakia	Always		Always	Always		Always	Always	
Slovenia	Always		Always	Always		Always	Always	
Spain	Always		Always	Always	1	Always	Always	
Sweden	Always		Always	Always	1	Always	Always	
Switzerland	Always		Always	Always		Always	Always	
UAE	Always		Always	Always		Always	Always	
United Kingdom	Always		Always	Always	1	Always	Always	
USA	Always		Usually	Usually		Always	Always	
USA	Andrays		osualiy	osuany		ruways	ra wa ys	

Upper-middle income

	BREAST	MELA	NOMA	LUNG		
Country	Trastuzumab +BS	Nivo	Pembro	Erlotinib	Gefitinib	Afatanib
Albania	Always		Half the time	Always	Never	Never
Argentina	Always	Always	Always	Always	Always	Usually
Armenia	Always	Always	Always	Always	Always	Usually
Azerbaijan	Always	Half the time	Half the time	Usually	Half the time	Occasionally
Belarus	Usually	Occasionally		Occasionally		
Bosnia + HGV	Usually	Usually	Usually	Always		Never
Botswana	Always		Usually			
Brazil	Always	Always	Always	Always	Always	Always
Bulgaria	Always	Always	Always	Always	Always	Always
China	Always	Always	Always	Always	Always	Always
Colombia	Always	Usually	Usually	Always	Always	Usually
Costa Rica	Usually	Never	Always	Occasionally	Occasionally	Never
Cuba						
Ecuador	Usually		Usually			Usually
Georgia	Always	Always	Always	Always	Never	Never
Guatemala	Usually					
Iraq	Usually	Usually	Usually	Usually	Usually	Occasionally
Jamaica	Usually	Usually	Usually	Usually	Usually	
Kazakhstan	Always	Occasionally	Always	Always	Always	Always
Libya		Occasionally	Half the time	Usually	Half the time	Occasionally
Malaysia	Always	Always	Always	Usually	Usually	Always
Mexico	Usually	Occasionally	Occasionally	Half the time	Half the time	Occasionally
Moldova						
Montenegro	Always		Always	Always	Always	
Namibia	Usually			Usually	Always	
North Macedonia	Usually	Never	Half the time	Usually	Usually	Never
Peru	Always	Always	Always	Always	Usually	Usually
Romania	Always	Usually	Usually	Always	Always	Always
Russia	Always	Usually	Usually	Always	Always	Usually
Serbia	Always	Usually	Usually	Always	Always	Always
South Africa	Usually	Never	Usually	Usually	Half the time	Never
Suriname	Occasionally					
Thailand	Usually	Usually	Usually	Always	Always	Usually
Türkiye	Always	Always	Always	Always	Always	Always
Turkmenistan	Occasionally	Never	Never	Never	Never	Never

Always	
Usually	
Half the time	
Occasionally	
Never	
Not available	

Low + Lower-middle income

Country

Algeria

Banglades Bolivia

Cambodia

Cameroon

Egypt El Salvado

Ghana Haiti

Honduras India

Indonesia

Iran

Kenya

Lebanon

Mongolia

Morocco Myanmar

Nicaragua

Nepal

Nigeria

Pakistan

Palestine

Papua Nev

Philippines Sri Lanka

Tunisia

Tanzania Uzbekistan

Vanuatu Vietnam

Zambia

Zimbabwe

Afghanista

Burkina Fa

Madagasca

Ethiopia

Liberia

Malawi

Rwanda

Somalia

Sudan

Syria

Uganda Yemen

Venezuela

Niger

	BREAST	MELA	NOMA		LUNG	
	Trastuzumab +BS	Nivo	Pembro	Erlotinit	Gefitinib	Afatani
	Always			Always	Always	
	Occasionally	Always	Half the time	Always	Always	Usually
	Usually			Occasionally	Occasionally	Occasional
	Always	Usually	Usually	Always	Always	Occasional
	Usually	Occasionally	Occasionally			
	Always	Usually	Usually	Half the time	Always	Occasional
	Half the time			Half the time	Occasionally	
	Always					
	Occasionally	Never	Never	Never	Never	Never
	Usually		Usually			
	Always	Never	Never	Never	Never	Never
	Always	Always	Always	Always	Always	Always
	Always	Always	Always	Always	Always	
	Half the time	25-50% cost	25-50% cost	Usually	Half the time	
	Usually					
	Always					
	Always		Always	Always	Always	Always
	Usually	Half the time	Half the time	Usually	Usually	Usually
	Usually	Occasionally	Occasionally	Usually	Usually	
	Always			Usually		
	Half the time	Always	Usually	Half the time	Half the time	Occasional
	Never	Never	Never	Never	Never	Never
Guinea	Occasionally			Occasionally	Occasionally	
	Always		Always	Always	Always	Always
	Usually					
	Always				Half the time	
	Never	Half the time	Half the time			
	Usually	Usually	Usually	Usually	Usually	Usually
	Usually					
	Usually	Never	Half the time	Usually	Usually	Usually
	Half the time			Never	Half the time	
	Occasionally					Never
0		Never	Never	Occasionally	Occasionally	Occasional
0	Never	Never	Never	Occasionally	Occasionally	Occasional
0	Never	Never	Never			
				Never	Never	Never
	Never Occasionally Never	Never Never	Never			
	Never Occasionally			Never	Never	Never
	Never Occasionally Never Occasionally	Never	Never	Never Never	Never	Never
	Never Occasionally Never Occasionally Always			Never	Never	Never
	Never Occasionally Never Occasionally Occasionally Always Never	Never	Never	Never Never	Never	Never
	Never Occasionally Never Occasionally Always	Never	Never	Never Never Occasionally	Never Never	Never
	Aever Occasionally Aever Occasionally Always Never Occasionally	Never	Never	Never Never Occasionally Half the time	Never	Never
0 	Never Occasionally Never Occasionally Occasionally Always Never	Never	Never	Never Never Occasionally	Never Never	Occasionali Never Never

RESULTS 2017



2017 ESMO INTERNATIONAL CONSORTIUM STUDY ON THE AVAILABILITY, OUT-OF-POCKET COSTS AND ACCESSIBILITY OF ANTINEOPLASTIC MEDICINES IN COUNTRIES OUTSIDE OF EUROPE

SPECIAL ARTICLE

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe

N. I. Cherny^{1*}, R. Sullivan², J. Torode³, M. Saar⁴ & A. Eniu^{5,6}


Annals of Oncology 28: 2633–2647, 2017



COST AND
AVAILABILITY OFMULTI-USEESSENTIALHiMEDICINES WHENPATIENT HAS A VALIDPRESCRIPTION


Free	
<25% cost	
25-50% cost	
Discount >50% and <100%	
Full cost	
Not available	
Missing data	

MADRID 2023



ACCESSIBILITY OF MULTI-USE ESSENTIAL MEDICINES

Always
Usually
Halfthe time
Occasionally
Never
Not available
Missing data



MADRID 2023

LESSONS LEARNED?



ESSENTIAL MEDICINES AFFORDABILITY IN LOW AND LOW-MIDDLE INCOME COUNTRIES



"Old, inexpensive" cancer medicines

> Often only at full cost as an out-of-pocket expenditure (OOP)



New expensive biological (ESMO-MCBS 4-5 scores and A –B scores) > Usually only at full cost as an out-of-pocket expenditure (OOP)

Not much has changed in the past 5 years

ESSENTIAL MEDICINES <u>ACCESSIBILITY</u> IN LOW AND LOW-MIDDLE INCOME COUNTRIES



"Old, inexpensive" cancer medicines

> Often unreliable

> Non-continuous availability and unreliable procurement



Not much has changed in the past 5 years

LIMITATIONS OF THE STUDIES

Macro-level study, covering a wide range of medicines with a timeconstrained 'snapshot' of the situation

There <u>may be differences</u> within each country Accuracy of data

Accuracy of the data is dependent on the reporting accuracy of field reporters and their due diligence in verification of facts

The methodology incorporated **measures to minimise error**, including multiple reporters and cross-checks between reporters, and a process of open peer-review



ADDRESSING DISCREPANCIES



Realising the aspirations of the WHO EML list for cancer medicines requires new approaches



Ellen't Hoen (Director at Medicines Law and Policy) on '**Policy and intellectual property** regulatory instruments as tools to enhance access to expensive essential cancer medicines'



Kiusiang Tay-Teo (Technical Officer, World Health Organization) on 'Governmental policies to control cancer medicine prices'



ACKNOWLEDGEMENTS

MADRID ES

Project Leader	49 Collaborating	Partners	ESMO Officers	ESMO Staff	Reporters
ESMO	 African Organisation for Research and Training in Cancer Albanian Oncology Association American Society of Clinical Oncology Armenian Association of Hematology and Oncology Argentine Association of Clinical Oncology Arsociation of Cancer Physicians Belgian Society of Medical Oncology Brazilian Society of Clinical Oncology Canadian Association of Medical Oncology Canadian Association of Medical Oncology Croatian Society of Medical Oncology Cyprus Oncology Society Czech Society for Oncology Danish Society of Medical Oncology Estonian Society of Medical Oncology Estonian Society of Oncology Pharmacy, coordinating with the International Society of Oncology Pharmacy Practitioners Finnish Society for Oncology German Society of Medical Oncology Hellenic Society of Medical Oncology Indian Society of Medical Oncology Indian Society of Medical Oncology Iranian Society of Medical Oncology Irsh Society of Medical Oncology Irsh Society of Medical Oncology Irsh Society of Medical Oncology Israeli Society of Medical Oncology Israeli Society of Clinical Oncology and Radiation Therapy 	 Italian Medical Oncology Association Japanese Society of Medical Oncology Korean Society for Medical Oncology Latvian Society for Medical Oncology Lithuanian Society of Oncology Luxembourg Society of Oncology Malaysian Oncological Society Medical Oncology Group of Australia Middle East Cancer Consortium Mexican Society of Oncology New Zealand Society for Oncology Norwegian Association of Oncology Philippine Society of Medical Oncology Polish Society of Medical Oncology Serbian Society of Medical Oncology Slovak Oncology Society Medical Oncology Society Serbian Society of Oncology Slovak Oncology Society Medical Oncology Society Medical Oncology Society Serbian Society of Oncology Slovak Oncology Society Medical Oncology Society of Oncology Swedish Society of Medical Oncology Swiss Society of Medical Oncology Swiss Society of Medical Oncology Taiwan Oncology Society Thai Society of Clinical Oncology Turkish Society of Medical Oncology 	 Nathan Cherny Elisabeth de Vries ESMO-MCBS WG: Dario Trapani Bishal Gyawali Felipe Roitberg ESMO Cancer Medicines Committee 	 Martina Galotti Nicola Latino Gracemarie Bricalli 	All reporters who have completed the survey and the peer review



THANK YOU

European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org

esmo.org